Sector News

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

May 15, 2022
Life sciences

Flagship Pioneering and Novo Nordisk A/S today announced a collaboration to create a portfolio of novel research programmes to develop transformational medicines.

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

This is a novel approach to collaboration, between companies providing extensive access to innovation, leveraging the technology platforms of multiple biotech companies to create a portfolio of medicines across several disease areas.

“We are excited about this new agreement which will give Novo Nordisk access to Flagships’ large and diverse portfolio of companies, representing a wide variety of novel cutting-edge technologies and therapeutic modalities,” said Marcus Schindler, PhD, professor, executive vice president and chief scientific officer of Novo Nordisk. “This is a new and innovative way of collaborating, which combines the strength of Flagship Pioneering’s bioplatforms with Novo Nordisk’s cardiometabolic and rare disease expertise.”

Novo Nordisk will provide funding for initiated research programmes and have an exclusive option to license each program. The ambition is to initiate three to five research programs within the first three years of the collaboration.

“We enter into this collaboration with Novo Nordisk with a shared vision of creating transformational medicines in disease areas where there continue to be significant needs,” said Paul Biondi, president, Pioneering Medicines and executive partner, Flagship Pioneering. “This strategic partnership demonstrates the unique advantages of our Pioneering Medicines model in which we bring together complementary capabilities and expertise from multiple companies to deliver life-changing medicines to patients.”

Through the collaboration, Flagship’s Pioneering Medicines and the Novo Nordisk Bio Innovation Hub will jointly select the most promising product concepts and conduct research programmes.

Pioneering Medicines is a strategic initiative within Flagship Pioneering that is dedicated to conceiving and developing a broad portfolio of life-changing treatments by leveraging and expanding the use of Flagship’s innovations.

The Novo Nordisk Bio Innovation Hub is a cross-functional R&D team within Novo Nordisk based in Cambridge, Massachusetts, with an ambition to establish and drive an externally anchored portfolio of co-created breakthrough therapeutic concepts and technologies and delivery projects. The Bio Innovation Hub, together with the recently acquired Dicerna Pharmaceuticals Inc. in Lexington, Massachusetts, are two of four transformational research units (TRUs) in the Novo Nordisk R&D organisation.

By Novo Nordisk, Press Release

Source: novonordisk.com

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).